Personalis, Inc. reported second-quarter 2026 results showing revenue of $22.36M, up 30% from $17.2M a year earlier, while the company recorded a net loss of $31.68M and diluted loss per share of $(0.30), both wider than the prior-year quarter.
Financial Highlights
- Revenue was $22.36M for Q2 2026, compared with $17.20M in Q2 2025; YoY change 30%.
- Net income was a loss of $31.68M for Q2 2026, compared with a loss of $20.06M in Q2 2025; worsened year over year.
- Diluted earnings per share was a loss of $(0.30) for Q2 2026, compared with $(0.23) in Q2 2025; more negative year over year.
Business Highlights
- Total revenue growth was driven by pharma services and increased clinical test reimbursements; pharma testing is now the company's largest channel.
- Enterprise revenue declined following completion of a project with Natera and scaled-down sequencing for a VA MVP effort.
- Clinical momentum included multiple Medicare coverage decisions across breast, lung, IO and NAT, supporting diagnostic uptake and reimbursement.
- Operational scale expanded with sequencing capacity above 350 trillion bases per week and roughly 605K samples sequenced (including 237K whole-genome sequences).
- Expanded collaborations and evidence generation with partners such as TRACERx, Moderna, Tempus and major cancer centers were cited as supporting adoption.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.